Literature DB >> 18048089

The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.

Krystyna Pawlak1, Michal Mysliwiec, Dariusz Pawlak.   

Abstract

INTRODUCTION: The urokinase-type plasminogen activator (uPA)/its soluble receptor (suPAR) and CC-chemokines are two systems contributing in the atherosclerosis. We try to establish whether these two systems were associated among themselves, and the significance of this potential association in relation to carotid atherosclerosis in uraemic patients.
MATERIALS AND METHODS: We determined uPA, suPAR, CC-chemokines: monocyte chemoattractant protein-1 (CCL2), macrophage inflammatory proteins (CCL3, CCL4), regulated upon activation, normal T cell expressed and secreted (CCL5) and the intima-media thickness (IMT) values in uraemic patients on peritoneal dialysis (CAPD), haemodialysis (HD) and healthy controls.
RESULTS: The values of the uPA/suPAR system, CCL2, CCL4 and IMT in the patients significantly exceeded those in controls, whereas CCL5 were lower in the patients than in the controls. CCL3 concentrations were similar in all investigated groups. CCL2, CCL4 and CCL5 were positively associated with uPA/suPAR system. CCL2 and CCL4 were associated with IMT. Multivariate analysis showed that uPA, suPAR and age were the strong independent variables linked to IMT values.
CONCLUSIONS: The carotid atherosclerosis is independently related to uPA/its soluble receptor system in dialysis patients. In addition, the strong positive associations existed between uPA/suPAR system and CC-chemokines suggesting that these two systems could cooperate and influence of atherosclerosis in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18048089     DOI: 10.1016/j.thromres.2007.10.017

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study.

Authors:  Carla M T Fourie; Johannes M Van Rooyen; Annamarie Kruger; Michael H Olsen; Jesper Eugen-Olsen; Rudolph Schutte; Aletta E Schutte
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

2.  Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.

Authors:  Moo Yong Park; Sandra M Herrmann; Ahmed Saad; Alfonso Eirin; Hui Tang; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 8.237

3.  Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.

Authors:  Massimo Alfano; Samanta A Mariani; Chiara Elia; Ruggero Pardi; Francesco Blasi; Guido Poli
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

4.  Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.

Authors:  Renáta M Böcskei; Béla Benczúr; György Losonczy; Miklós Illyés; Attila Cziráki; Veronika Müller; Anikó Bohács; András Bikov
Journal:  Lung       Date:  2019-02-28       Impact factor: 2.584

5.  Vascular Structure and Inflammation in a South African Population: The SABPA Study.

Authors:  Carla Swart; Leandi Lammertyn; Paul I Welsh; Shani Botha-Le Roux
Journal:  Pulse (Basel)       Date:  2019-07-10

6.  Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans.

Authors:  Michel T Corban; Abhiram Prasad; Lisa Nesbitt; Darrell Loeffler; Joerg Herrmann; Lilach O Lerman; Amir Lerman
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.